Aims: To compare the glycaemic outcomes of 2 glucose-lowering treatment strategies in vulnerable (moderately ill and/or frail) patients aged ≥65 years with type 2 diabetes whose individual HbA1c targets were not met with diet/exercise and/or oral anti-hyperglycaemic medications (OAMs).
| INTRODUCTION
Diabetes global prevalence is~20% in people aged 65 to 79 years, 1 most have type 2 diabetes (T2D), and rates are increasing. [2] [3] [4] Such patients are often vulnerable because of comorbid conditions and/or frailty. 5, 6 Lowering blood glucose (BG) is a mainstay of treatment, regardless of age and functional status. 7, 8 In older patients, the main objective is to avoid/minimize symptoms and potential complications of hyperglycaemia. 6, 9 Older individuals are also prone to hypoglycaemia, 10 consequences of which can be severe. 11 Optimal management in this population is difficult to define, however, largely because patients with frailty and/or significant 2 | METHODS
| Study design
This randomized, multinational, open-label, in-label, active-controlled, parallel-group study involved moderately ill and/or frail older patients.
The primary objective was to assess relative success of 2 treatment strategies in achieving/maintaining glycaemic control without "clinically significant hypoglycaemia." The study, which was planned to continue for 72 weeks ( Figure S1 ), was preceded by an internal pilot phase (described in this paper) that included~20% of the planned full study population who were treated for ≥24 weeks. Once this number was reached, enrollment in the full study was paused and an interim analysis was conducted. Enrollment was to resume if interim results indicated feasibility of the full study. Interim results (unblinded efficacy and safety data) were evaluated by an internal Data Monitoring
Committee (DMC).
The study was conducted according to the ethical principles of the Declaration of Helsinki and Council for International Organisations of Medical Science International Ethical Guidelines, the International Conference on Harmonisation Good Clinical Practice
Guidelines, and applicable laws and regulations. Participating investigators are listed in Appendix S1.
| Eligibility criteria
Eligible patients (male or female) were ≥65 years with T2D, HbA1c >7.3% (56 mmol/mol) and <10.9% (96 mmol/mol) and ≥0.4% 
| Selection of individualized HbA1c target
For each individual, treatment aimed at achieving and maintaining individualized, preset HbA1c target ranges, while avoiding hypoglycaemia. Individual HbA1c targets (7.5%-7.9%, 7.0%-7.4%, and <7%)
were determined at screening. HbA1c targets were ultimately at investigator discretion, based on presence of comorbidities and complications, cognitive status, life expectancy, duration of diabetes, functional status, and hypoglycaemic risk, and were agreed between investigator and patient at screening. Guidelines for selection of individualized treatment targets are available online (Appendix S2).
| Treatment
Investigators were provided general management rules and guidance for using study treatments according to locally-approved product labels; however, within a given strategy, choice of specific treatments and their combinations was at their discretion. Self-monitoring of BG was performed at the discretion of the investigator. Metformin, pioglitazone, DPP-4 inhibitors, and acarbose could be used in either strategy; other anti-hyperglycaemic medications, including SGLT-2 inhibitors, were excluded from both strategies.
Some pre-study treatments were replaced at study entry: rosiglitazone was replaced with pioglitazone, and DPP-4 inhibitors other than linagliptin or sitagliptin, were replaced with either of these. For patients randomized to Strategy-B, sulphonylureas other than glimepiride, were replaced with this medication, while in Strategy-A, sulphonylurea was stopped and replaced with other OAMs. These and other treatments were continued throughout the study.
| Outcome measures
The primary outcome was a composite of achieving and maintaining individualized HbA1c targets without "clinically significant" hypoglycaemia. This was defined as any one of the following: (1) <60 mL/min/1.73 m 2 or albumin-to-creatinine ratio > 30 mg/g), progression of DKD (≥30% decrease in eGFR from baseline/increased albumin-to-creatinine ratio from ≤30 mg/g at baseline to >30-300 mg/g post-baseline), 30, 31 and incidence of adverse events.
| Statistical analysis
Demographic and baseline characteristics data were summarized using descriptive statistics. Categorical analyses were performed using chi-squared or Fisher's exact test.
Logistic regression with treatment target, country, and baseline A pre-defined interim analysis was to be performed when~142 patients completed 24 weeks of treatment. Conditional power (CP) was calculated to determine the feasibility of the full study and was defined according to prespecified protocol criteria. If the CP was "promising" (0.20-0.95), the study was continued and sample size was increased to a maximum of 660 completed patients; if "favourable" (>0.95), the study was continued using the planned sample size of 500 completed patients; if "unfavourable" (<0.20), the study was terminated.
3 | RESULTS
| Patients
In total, 388 patients were enrolled/screened from February 2014 to (Tables 1 and S1 ).
| Study treatment
At final analysis patients had received treatment for a median dura- 
| Primary outcome
The primary outcome was not significantly different between treatment strategies (A, 68.9% vs B, 65.9% of patients; P = .666) at the pre-defined interim analysis. This lack of a difference between strategies in treatment success was apparent in each of its components:
failure to achieve and maintain individualized glycaemic targets and similar percentages of patients with "clinically significant" hypoglycaemia in both strategies. Further analysis yielded a CP of 0.05, indicating an "unfavourable" probability of demonstrating a difference between strategies in treatment success, even if the sample size was increased for the full study. On the basis of these results and recommendations from the DMC, the study was discontinued. Once the decision to stop the trial was made, patients were asked to come for their next scheduled study visit which was considered final.
For the primary outcome at final analysis ( Table 3 ). There were no significant differences between treatment strategies in proportions of patients reaching/maintaining HbA1c target at last visit, or in HbA1c change from baseline to endpoint (Table 3) .
| Safety
Incidences of total, documented symptomatic, and asymptomatic hypoglycaemic events were significantly lower in Strategy-A than in 
• Withdrawal by subject (N = 7)
Completed study (N = 14)
Completed study (N = 15) were not statistically significant.
Proportions of patients with ≥1 treatment-emergent adverse event (TEAE) were similar for both strategies (A, 84.7%; B, 79.6%), while treatment-related TEAEs occurred more frequently in Strategy-A (27.6% vs 8.6%, P < .001). The most frequent TEAEs (≥5% of patients in either strategy) are summarized in Table 4 . The gastrointestinal TEAEs, diarrhoea (12.2% vs 6.5%) and nausea (7.1% vs 3.2%),
were more common for Strategy-A. Falls resulting in TEAEs occurred in 9.2% and 9.7% of patients in Strategy-A and Strategy-B, respectively, but none were considered related to hypoglycaemia.
Seven patients were discontinued because of an adverse event Data are presented as mean AE SD or n (%) unless otherwise indicated.
The distribution of patients by TIBI and CFS scores by treatment strategy is provided in Table S1 in the online supporting information. a n = 98 for glucose-dependent strategy. Data are presented as n (%).
a Maximum line of therapy.
b These patients (protocol violations) were included in the analysis as the small numbers in each strategy were not anticipated to effect the study results.
There was no difference between strategies in proportions of patients with kidney disease at study endpoint (A, 39.8%; B, 45.2%; P = .453), or in evidence of disease progression (A, 10.2%; B, 11.8%; P = .720).
| DISCUSSION
A significant challenge in treating older patients with diabetes is achieving glucose targets without increased risk of hypoglycaemia.
We report the results of the first study attempting to compare benefits and risks of treatment strategies available in a group representative of the older population. The study aimed at assessing whether a glucose-dependent (Strategy-A) versus a non-glucose-dependent Adjusted % (95% CI)/P-value, Strategy-A vs Strategy-B Abbreviations: CI, confidence interval; HbA1c, glycated haemoglobin; OAM, oral anti-hyperglycaemia medication; LS, least square; SD, standard deviation; SE, standard error.
Adjusted proportions and P-values were based on a logistic regression model with treatment target, country, and baseline HbA1c as covariates.
a Treatment strategy was considered a success if HbA1c target was reached/maintained with no clinically significant hypoglycaemia.
b Treatment (Strategy-A vs Strategy-B) was considered "promising" for a conditional power (CP) of 0.20-0.95, "favourable" for a CP > 0.95, and "unfavourable" for a CP < 0.20.
c Patients could have been counted in more than 1 category.
d Individualized HbA1c treatment target was not reached/maintained upon 2 consecutive determinations starting from week 24 for patients with data beyond week 24, or not reached at week 24 for patients without data beyond week 24.
e One patient in Strategy-A did not have a treatment record as this patient was discontinued for a protocol violation (week 4) but was included as a treatment failure because the HbA1c target was not met at the last available visit.
HbA1c was 7.2% in each cohort. Improved glucose control was achieved with no clinically significant hypoglycaemia. However, it was evident from the interim results that Strategy-B confers a significantly greater hypoglycaemia risk pertaining to categories other than clinically significant episodes (ie, total, symptomatic, asymptomatic).
Hypoglycaemic events are typically assigned different degrees of clinical importance, but information continues to emerge that suggests all such episodes may be relevant. For example, recent data have shown increased risk of cardiac arrhythmias in association with both asymptomatic episodes with interstitial glucose levels <3.1 mmol/L ("severe episodes") 32 and nocturnal 33 hypoglycaemia.
Given that any hypoglycaemic event may be considered "clinically relevant," particularly in older, vulnerable populations, hindsight leads us to question whether our choice of primary endpoint was too stringent or restrictive in this study. Moreover, it is unlikely that, had "any hypoglycaemic episode" been used in the primary endpoint, the study would have been stopped on the basis of futility; however, this can only be confirmed in future studies designed to investigate benefits and risks of these 2 strategies in vulnerable, older patients. Given the frequent occurrence of asymptomatic hypoglycaemia in older patients, use of continuous glucose monitoring (CGM) in all patients in this study may have yielded some valuable data. Indeed, a subset of patients in this study were monitored by CGM and the results have been reported separately. 34 The major value of this study lies in the lessons learned that can be applied to the conduct of future studies. As such, we examined this study's limitations.
The first important point relates to the study population. Enrolled patients were generally younger and less frail than anticipated for The planned treatment period of the interim analysis (24 weeks) is another factor that may have contributed to failure to achieve glycaemic control in some patients. Given the recommendation that
anti-hyperglycaemic medication titration should be initiated at low doses in older patients and titrated slowly, allowing up to 3 months between changes in medication, 16 it is possible that the minimum study duration (ie, 24 weeks) was not long enough for clinicians to achieve the desired degree of glycaemic control, although the median duration was 42 weeks. Notably, per the final protocol for the full study, 36 weeks was considered sufficient time to reach the HbA1c target, even for those patients requiring multiple dose adjustments and changes of therapy (ie, additions of OAMs).
In conclusion, when "success" is defined as a combination of glycaemic control and absence of "clinically significant" hypoglycaemia (as defined in this study), treatment strategies involving glucosedependent and non-glucose-dependent anti-hyperglycaemic medications result in similar success rates in vulnerable older patients with T2D. However, total, documented symptomatic, and asymptomatic hypoglycaemia were significantly less frequent in Strategy-A, a finding that, upon reflection, is clinically relevant in a patient population in which hypoglycaemia can have serious implications. The results of this study will also inform future clinical research in older patients with T2D.
